The clinical research results of an innovative new drug to treat rare diseases under development by Hanmi Pharm have been selected as the cover paper of the SCI international journal.
Hanmi Pharmaceutical announced today that the clinical results of LAPS Glucagon Analog, which is being developed as an innovative new drug for the treatment of congenital hyperinsulinemia, were listed in the March 2022 issue of the SCI international journal "DOM, Diabetes, Obesity and Metabolism".
The journal also selected the research contents as the cover paper in consideration of the potential and innovativeness of LAPS Glucagon Analog.
LAPS Glucagon Analog is being developed as a treatment for rare hypoglycemic diseases such as congenital hyperinsulinemia with the goal of being administered once a week for the first time in the world.
This paper is a study that evaluated the safety, tolerability, and pharmacokinetics of five doses in 56 healthy subjects.
According to the study, LAPS Glucagon Analog significantly increased fasting blood glucose levels up to 17 days.
This shows the potential to extend the dosing cycle to two weeks beyond the world's first weekly administration, which is the development goal of Hanmi Pharmaceutical.
LAPS Glucagon Analog did not cause serious side effects at any dose, confirming excellent safety and tolerability.
Currently, Hanmi Pharm is conducting additional phase 2 clinical studies to confirm the potential benefit of LAPS Glucagon Analog in patients with rare hypoglycemia.
